Results 71 to 80 of about 6,174 (184)
Targeting Oncogenic RAS Signaling in Pancreatic Cancer : Interaction of small molecular inhibitors in the presence and absence of irradiation [PDF]
, 2023 Pancreatic ductal adenocarcinomas account for 80−90% of all pancreatic malignancies and are among the most lethal of cancers known to date. They are driven by oncogenic KRAS mutations in over 90% of cases, which have been linked to early metastasis and ...
Wang, Xuan
core
Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale
Journal of Cutaneous Pathology, Volume 53, Issue 3, Page 224-229, March 2026.ABSTRACT Melanoma microsatellites are peritumoral metastatic deposits and surrogates for potentially aggressive biological behavior. Their presence indicates clinical stage III disease. They are rarely reported in association with thin primary tumors (< 1.0 mm, pT1).
Angela Cheng +5 more
wiley +1 more source
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
Translational Oncology, 2020 BRAFV600-mutated colorectal cancer (CRC) accounts for 8% to 12% of all CRC diagnoses. These tumors are often associated with specific patient features, including right-sided primary tumor location, peritoneal and non-regional lymph node involvement, and ...
Giandomenico Roviello +7 more
doaj +1 more source
Precision medicine in cutaneous melanoma—A comprehensive review
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 377-386, March 2026.Precision medicine tailors treatment to each patient, beginning with detailed diagnostics. In melanoma, it has advanced considerably: Some methods are in practice and guidelines, while others are commercially available but not routine. This review highlights current and emerging approaches, including molecular profiling, imaging, biomarkers and AI ...
Markus Reitmajer, Lukas Flatz
wiley +1 more source
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18:Enzymes [PDF]
, 2017 The Concise Guide to PHARMACOLOGY 2017/18 provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to an open access knowledgebase of drug targets and ...
, +11 more
core +15 more sources
, 2020 Until fairly recently, treatment options for advanced melanoma have been relatively limited. Fortunately, the last decade has seen dramatic improvements in response rates and duration of overall survival after the introduction of checkpoint inhibitors ...
Chandra, Sunandana +2 more
core +1 more source
The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo. [PDF]
, 2019 Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 15% of all pediatric cancer-related deaths. New therapies are needed to improve outcomes for children with high-risk and relapsed tumors. Inhibitors of the RET kinase
Flynn, Sean M +7 more
core
Case Reports in OncologyIntroduction: Encorafenib and binimetinib, a combination of BRAF and MEK inhibitors, is a standard of care for patients with advanced BRAFV600-mutant melanoma.
Chloe Wautier +3 more
doaj +1 more source
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 4, Page 693-694, April 2026.
Francisco Martins +1 more
wiley +1 more source
Cancer Science, Volume 117, Issue 1, Page 246-256, January 2026.This study develops an immunohistochemistry (IHC)‐based classification system for BRAF V600E‐mutant colorectal cancer, enabling practical stratification into iBM1 and iBM2 subtypes using CD8 and ARHGEF17 markers. The IHC‐defined subtypes demonstrated concordance with transcriptomic BM1/BM2 classifications and reflected distinct molecular and immune ...
Chao Liu +11 more
wiley +1 more source